The slip
PARKINSON RECEIPTno. 11524
27 Oct 2026, 03:43 UTCdopamine neurons, braak
predictionMFSD1 in dopamine neurons tracks Braak Lewy-body stage
registeredc68116f6add98433
discovery+0.49 p=0.182 n=9
replication-0.16 p=0.689 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho +0.49, p 0.182)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECTf0292cbbde12ac82367c4196…
follows b2d832406628…
Covered by the on-chain checkpoint of receipt 11527 (2026-10-27 03:47 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 11524: MFSD1 in dopamine neurons, braak
- power
- full sample +0.21 (p 0.408, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.24 (p 0.337, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.273, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.32, sign flips 0; without severely affected donors +0.21 (p 0.408, n 18). fragile.
- cell type
- strongest in oligodendrocytes: +0.67 (p 0.0022, n 18) vs +0.21 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MFSD1 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up MFSD1 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.30 p 0.286 (needs p < 1.9e-4)